The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are: * Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation? * Which treatment better controls blood flow while causing fewer side effects? Researchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small liver grafts. Participants will: * Be randomly assigned to receive either octreotide or splenic artery ligation during their transplant surgery * Have their liver blood flow monitored closely during and after surgery Be followed for 90 days and 1 year to track complications, hospital stay, recovery, and survival. This study may help doctors choose safer, more effective treatments for patients needing small liver grafts.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Median Comprehensive Complication Index® (CCI®)
Timeframe: From the day of liver transplantation (Day 0) through postoperative day 90.
Small-for-size syndrome (SFSS) rate
Timeframe: From the day of liver transplantation (Day 0) through postoperative day 14
Number and proportion of postoperative complication types and grades within 90 days
Timeframe: From the day of liver transplantation (Day 0) through postoperative day 90
Adequate portal flow modulation response rate
Timeframe: From intervention completion (T=0) to 60 minutes post-intervention
Mortality rate
Timeframe: From the day of liver transplantation (Day 0) through postoperative day 90